Singapore Clinical Trial: A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy and safety of MLC901 (NeuroAiD™II) in subjects with mild to moderate Alzheimer’s Disease (AD).

Singapore, Sept. 5 -- The Health Sciences Authority received information related to the study titled 'A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy and safety of MLC901 (NeuroAiD™II) in subjects with mild to moderate Alzheimer’s Disease (AD).'. The following are the other relevant details related to the trial:

Therapeutic Area: Neurology

Trial Centre(s): National Neuroscience Institute National University Hospital

Trial Status: NA

Principal Investigator(s): Dr Ng Su Lyn Adeline Dr Christopher Chen Li-Hsian

Published by HT Digital Content Services with permission from Health Daily Digest....